Coloplast CEO on expectations: "There are many swing factors"
When Coloplast's CFO Anders Lonning-Skovgaard looks from one Covid-stricken year to the next, he assumes that health authorities worldwide have improved their ability to handle the coronavirus pandemic and that Coloplast and its growth target will be less affected than previously, if infections and hospitalizations go back on the rise.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
After a year of troubled waters because of the Covid-19 pandemic, Coloplast has a feeling it's headed towards a more positive and stable time. The Danish medtech firm has positive expectations for the coming fiscal year, where it aims to have organic growth at 7-8 percent and earnings at between 31-32 percent.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
